Zacks Investment Research upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
PRTK has been the subject of a number of other reports. LADENBURG THALM/SH SH reaffirmed a buy rating and issued a $18.00 price objective on shares of Paratek Pharmaceuticals in a research report on Tuesday, December 18th. ValuEngine cut Paratek Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 2nd. Canaccord Genuity started coverage on Paratek Pharmaceuticals in a report on Wednesday, January 2nd. They set a buy rating and a $14.00 price target for the company. Finally, HC Wainwright dropped their price target on Paratek Pharmaceuticals from $55.00 to $22.00 and set a buy rating for the company in a report on Friday, November 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Paratek Pharmaceuticals has an average rating of Buy and an average price target of $24.67.
PRTK opened at $7.14 on Wednesday. Paratek Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $15.45. The company has a market capitalization of $229.48 million, a PE ratio of -2.16 and a beta of 1.55. The company has a quick ratio of 11.39, a current ratio of 11.39 and a debt-to-equity ratio of 3.97.
In other Paratek Pharmaceuticals news, VP William M. Haskel sold 4,132 shares of the firm’s stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $6.64, for a total transaction of $27,436.48. Following the transaction, the vice president now owns 131,775 shares in the company, valued at approximately $874,986. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Chairman Michael Bigham sold 8,400 shares of the firm’s stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $6.76, for a total value of $56,784.00. Following the transaction, the chairman now owns 256,467 shares in the company, valued at approximately $1,733,716.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,506 shares of company stock valued at $275,601. 6.20% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of PRTK. JPMorgan Chase & Co. boosted its holdings in shares of Paratek Pharmaceuticals by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock valued at $3,271,000 after acquiring an additional 20,476 shares in the last quarter. Vanguard Group Inc lifted its holdings in Paratek Pharmaceuticals by 3.2% during the 3rd quarter. Vanguard Group Inc now owns 1,392,044 shares of the specialty pharmaceutical company’s stock worth $13,504,000 after buying an additional 43,816 shares during the period. Northern Trust Corp lifted its holdings in Paratek Pharmaceuticals by 13.1% during the 2nd quarter. Northern Trust Corp now owns 408,846 shares of the specialty pharmaceutical company’s stock worth $4,170,000 after buying an additional 47,440 shares during the period. General American Investors Co. Inc. lifted its holdings in Paratek Pharmaceuticals by 12.9% during the 3rd quarter. General American Investors Co. Inc. now owns 436,364 shares of the specialty pharmaceutical company’s stock worth $4,233,000 after buying an additional 50,000 shares during the period. Finally, Water Island Capital LLC lifted its holdings in Paratek Pharmaceuticals by 53.5% during the 3rd quarter. Water Island Capital LLC now owns 439,726 shares of the specialty pharmaceutical company’s stock worth $4,265,000 after buying an additional 153,226 shares during the period. Hedge funds and other institutional investors own 74.09% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.